Oramed Pharmaceuticals Inc. Common Stock (ORMP) Stock
Key stats
- Market cap
- $171.80M
- Price / Earnings ratio
- 0.9x
- EPS (TTM)
- $4.23
- Volume
- Loading
- 52-week high
- $5.47
- 52-week low
- $2.23
Source: third-party data provider, as of November 13, 2026
Compare with ORMP
Recent news

LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years
LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years
ORMP

Best Penny Stocks To Buy Today? 4 To Watch Under $5
Best Penny Stocks To Buy Today? 4 To Watch Under $5
ORMP
Technical indicators
- RSI 14
- 48.63
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.01
- SMA 50
- $4.41
- Price below SMA 50
- EMA 50
- $4.27
- Price below EMA 50
- SMA 200
- $4.05
- Price above SMA 200
- EMA 200
- $3.96
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years
LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years
ORMP

Best Penny Stocks To Buy Today? 4 To Watch Under $5
Best Penny Stocks To Buy Today? 4 To Watch Under $5
ORMP
About Oramed Pharmaceuticals Inc. Common Stock
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Nadav Kidron Esq. | President, CEO & Executive Chairman | 1974 |
| Mr. Avraham Gabay | CFO, Treasurer & Secretary | 1985 |
| Mr. Joshua Hexter | Chief Operating & Business Officer | 1970 |
| Dr. Miriam Kidron Ph.D. | Chief Scientific Officer & Director | 1940 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 48.63
- MACD 12/26/9
- -0.10
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.01
- SMA 50
- $4.41
- Price below SMA 50
- EMA 50
- $4.27
- Price below EMA 50
- SMA 200
- $4.05
- Price above SMA 200
- EMA 200
- $3.96
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | -11.7 | +14.4 | -3.7 | -8.3 | +3.2 |
Corporate actions
Upcoming
No upcoming corporate actions for ORMP



